For In Vitro Diagnostic Use. Rx Only.
Rates of sexual health conditions are rising across the globe – and creating bottlenecks in laboratories. Already under pressure to be more productive and innovative, every diagnostic lab must step up to expand testing and support care to create new value.
Where will you find the time? By identifying and eliminating the time traps in sexual health workflows.
Manual Processes and Error Prone Workflows
Different Collection Tubes
Different Sample Types
Disparate Instruments
Add On Testing
Workflows Across Departments
False Positives That Lead To Unneccessary Follow-ups and Procedures
False Negatives Due To Inadequate Sample Collection and Assay Performance
Find the steps that are consuming excessive time and limiting your team's capacity to expand testing and services
Screen for 14 high-risk HPV genotypes with 1 workflow. With extended genotyping, broken into ¥ strategic groups, you have new power to distinguish between new and persistent infections and help stratify high-risk patients for follow-up care.
7 strategies for redefining your lab workforce
It's time for laboratorians to start thinking like entepreneurs
A new opportunity to convert your health system lab from a cost center to a revenue driver.
References:
1. STIs in 2022: emerging and re-emerging outbreaks. World Health Organization. September 2, 2022. STIs in 2022: emerging and re-emerging outbreaks (who.int). Accessed December 6, 2023.
2. Gomah ME, Turley JP, Lu H, et al. Modeling Complex Workflow in Molecular Diagnostics. J Mol Diagn. 2010 Jan; 12(1): 51-57.
3. de Sanjose S, Serrano B, Tous S, et al. Burden of Human Papillomavirus (HPV)-Related Cancers Attributable to HPVs 6/11/16/18/31/33/45/52 and 58. JNCI Cancer Spectr. 2019 Jan 7;2(4):pky045.
4. Demarco M, Hyun N, Carter-Pokras O, et al. A study of type-specific HPV natural history and implications for contemporary cervical cancer screening programs. EClinicalMedicine. 2020 Apr 25:22:100293.
5. Valencak AO, Sterbenc A, Seme K, et al. Alinity m HR HPV Assay Fulfills Criteria for Human Papillomavirus Test Requirements in Cervical Cancer Screening Settings. J Clin Microbiol. 2019 Dec 23;58(1):e01120-19.
6. Perkins RB, Went¢ensen N, Guido RS, et al. Cervical Cancer Screening: A Review. Perkins et al., Cervical Cancer Screening. JAMA. 2023;330(6):547-558.
7. Bruni L, Albero G, Rowley J, et al. Global and regional estimates of genital human papillomavirus prevalence among men: a systematic review and meta-analysis. Lancet Glob Health. 2023 Sep;11(9):e1345-e1362. doi: 10.1016/S2214-109X(23)00305-4.
8. Huai P, Li F, ChuT, et al. Prevalence of genital Chlamydia trachomatis infection in the general population: a meta-analysis. BMC Infect Dis. 2020;20:589. Prevalence of genital Chlamydia trachomatis infection in the general population: a meta-analysis | BMC Infectious Diseases | Full Text (biomedcentral.com)
9. Kirkcaldy RD, Weston E, Segurado AC, et al. Epidemiology of Gonorrhea: A Global Perspective. Sex Health. 2019 Sep; 16(5): 401-411. doi: 10.1071/SH19061.
10. Poole, DN, McClelland RS. Global epidemiology of Trichomonas vaginalis. BMJ Journals. Sexually Transmitted Infections. 2013;89:418-422. Global epidemiology of Trichomonas vaginalis | Sexually Transmitted Infections (bmj.com)
11. Baumann L, Cina M, Egli-Gany D, et al. Prevalence of Mycoplasma genitalium in different population groups: systematic review and meta-analysis. Sex Transm Infect. 2018 Jun; 94(4): 255–262. doi: 10.1136/sextrans-2017-053384.
12. Govender RD, Hashim MJ, Khan MAB, et al. Global Epidemiology of HIV/AIDS: A Resurgence in North America and Europe. 2021 Sep; 11(3): 296–301. doi: 10.2991/jegh.k.210621.001.
13. TRaining to build community capacity to meaningfully engage in mpox response. World Health Organization. June 13, 2023. https://www.who.int/news/item/13-06-2023-training-to-build-community-capacity-to-meaningfully-engage-in-mpox-response. Accessed December 6, 2023.
14. Salari N, Kazeminia M, Hemati N, et al. Global prevalence of hepatitis C in general population: A systematic review and meta-analysis. Trv Med and Infec Dis. 2022;46. Global prevalence of hepatitis C in general population: A systematic review and meta-analysis - ScienceDirect
15. Global, regional, and national burden of hepatitis B, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. The Lancet. 2022;7(9): 796-929. Global, regional, and national burden of hepatitis B, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019 - The Lancet Gastroenterology & Hepatology
Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott. The website that you have requested also may not be optimised for your screen size.
Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions.
